文献速递腹部技术与安全CT

胰腺导管腺癌术后基线CT表现识别局部区域复发的效能及观察者间一致性评估

Evaluation of the performance of and interobserver agreement on postoperative baseline CT findings in the identification of locoregional recurrence in patients with pancreatic ductal adenocarcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2023-07-30

本研究评估198例胰头导管腺癌Whipple术后第3个月基线CE-MDCT图像,由三名放射科医师独立评价局部区域复发可疑征象,并分析其预测价值。结果显示血管周围强化实性组织、淋巴结及门静脉狭窄与早期局部区域复发相关,其中血管周围强化实性组织在多因素分析中OR为2.519。

要点

  • 术后第3个月基线CE-MDCT上出现血管周围强化实性组织、淋巴结及门静脉狭窄可能提示早期局部区域复发。
  • 血管周围强化实性组织在多因素分析中OR为2.519(95%CI 1.132-5.605,P=0.024)。
  • 实性组织形态的观察者间一致性差,评估时需谨慎。

核心结论

  • 术后基线CE-MDCT上手术床出现实性组织、淋巴结及门静脉狭窄是可能提示胰腺导管腺癌患者早期局部区域复发的表现。

研究设计与样本

  • 回顾性评估198例因胰头肿瘤行Whipple手术患者的术后第3个月基线CE-MDCT图像,由三名放射科医师独立评价,参考标准为腹部放射学会2022年10月指定的可疑复发征象。

关键影像表现/征象

  • 评价的CE-MDCT征象包括术后脂肪条索、血管周围强化实性组织(存在时记录短径及形态凸/凹)、腹膜种植、胰管扩张直径、大于5 mm淋巴结、门静脉狭窄(≥50%和<50%)、腹水及远处转移。

诊断标准与关键数值

  • 单因素分析示门静脉狭窄OR=1.419(95%CI 0.548-3.679,P=0.041)、淋巴结存在OR=2.337(95%CI 1.165-4.686,P=0.015)、血管周围强化实性组织OR=2.241(95%CI 1.072-4.684,P=0.005);多因素分析示血管周围强化实性组织OR=2.519(95%CI 1.132-5.605,P=0.024)。

临床应用与阅片要点

  • 阅片时需关注手术床血管周围强化实性组织、淋巴结及门静脉狭窄,实性组织形态的一致性差,报告时需注意。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate interobserver agreement on the findings of baseline contrast-enhanced multidetector computed tomography (CE-MDCT) performed at the postoperative third month in patients who underwent surgery due to ductal adenocarcinoma of the pancreatic head and investigate the value of these findings in predicting locoregional recurrence.

MATERIAL AND METHODS: The baseline CE-MDCT images of 198 patients who underwent the Whipple procedure due to pancreatic head tumors were evaluated independently by three radiologists at the postoperative third month. The radiologists were asked to note suspicious findings in terms of locoregional recurrence, including postoperative fat stranding, the presence of perivascular contrast-enhanced solid tissue, short diameter of solid tissue if present, the shape of solid tissue (convex/concave), presence of peritoneal implants, diameter (mm) of pancreatic duct dilatation if present, the presence of lymph nodes larger than 5 mm, portal vein stenosis (≥50 and <50%), the presence of ascites, and the presence of distant metastases, as specified by the Society of Abdominal Radiology in October 2022. The agreement between the radiologists and the value of these parameters in predicting locoregional recurrence were investigated.

RESULTS: Among the CE-MDCT findings evaluated, the radiologists had a moderate-to-high level of agreement concerning the presence of perivascular contrast-enhanced solid tissue. However, there was a poor interobserver agreement on the shape of solid tissue. A very high level of agreement was found among the radiologists in the evaluation of pancreatic duct dilatation, peritoneal implants, ascites, and the presence of distant metastases. According to the univariate analysis, the rates of portal vein stenosis had a 1.419 -fold effect [odds ratio (OR)=1.419, [95% confidence interval (CI)= 0.548-3.679, p=0.041], lymph node presence had a 2.337 -fold effect [odds ratio (OR)=2.337, [95% confidence interval (CI)= 1.165-4.686, p=0.015], perivascular contrast-enhanced solid tissue had 2.241 -fold effect [odds ratio (OR)=2.241, [95% confidence interval (CI)= 1.072-4.684, p=0.005]. In the multivariate analysis, perivascular contrast-enhanced solid tissue had 2.241 -fold effect [odds ratio (OR)=2.519, [95% confidence interval (CI)= 1.132-5.605, p=0.024].

CONCLUSION: In the postoperative baseline CE-MDCT examination, the presence of solid tissue, lymph node presence, and portal vein stenosis in the surgical bed are among the findings that may indicate early locoregional recurrence in patients with pancreatic ductal adenocarcinoma.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Akkaya H, Özdemir S, Dilek O, et al. Evaluation of the performance of and interobserver agreement on postoperative baseline CT findings in the identification of locoregional recurrence in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY). 2023. PMID: 37517056. doi:10.1007/s00261-023-04012-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。